Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | GLS | O94925 | 8/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16945285 | 0.90 | PPARA (0.53) | PPARGPPARDPPARA | |
| SCHEMBL16945273 | 0.88 | LMNA (0.54) | ROCK2ROCK1MMP13 | |
| SCHEMBL16945334 | 0.87 | MAPK14 (0.52) | MAPK14MMP13PPARGPPARDPPARA | |
| SCHEMBL16945305 | 0.86 | LMNA (0.45) | ROCK2ROCK1MMP13 | |
| SCHEMBL16945312 | 0.86 | ROCK1 (0.51) | ROCK2ROCK1 | |
| SCHEMBL16945287 | 0.86 | CCR1 (0.49) | MAPK14RIPK1 | |
| SCHEMBL16945336 | 0.85 | MMP13 (0.46) | MAPK14MMP13 | |
| SCHEMBL16945269 | 0.85 | SCD (0.50) | — | |
| SCHEMBL16945335 | 0.83 | PPARG (0.46) | MAPK14MMP13PPARGPPARDPPARA | |
| SCHEMBL16945280 | 0.83 | KMT2A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875029-B1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | MORASKI GARRETT (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9605002-B2 | 5,5-heteroaromatic anti-infective compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605002-B2 | 5,5-heteroaromatic anti-infective compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC | 2015-07-30 | — | — | US | disclosed |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | API5, CASP5, IL5 | MAPK14 3090/4885ROCK2 3440/4885ROCK1 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.